Get started with Myriad Oncology

Request more information from our team or explore ordering options and resources to bring Myriad Oncology testing into your practice.

Request information

GERMLINE AND TUMOR GENOMIC TESTING WITH MYRIAD

Each step. Every patient.
Exactly what you need

You rely on specific and clinically actionable oncology test answers to ensure that each patient receives the personalized, stage-specific interventions they need. Myriad has built a comprehensive oncology-focused genetic and tumor genomic testing portfolio to do just that. Designed to empower you at each step across their patient journey — from screening to treatment, from previvorship to survivorship — we provide the insights you count on, with extensive patient and staff support services along the way.

Myriad Oncology empowers you to transform patient care

We offer a suite of services and workflow solutions designed to streamline germline and tumor genomic testing without added cost to the clinic or patient.

Accurate, useful results

  • Accurate, reliable, and actionable results to support informed decisions
  • Clear and easy-to-interpret reports for confident clinical direction
  • Lifetime commitment to variant reclassification

Unmatched customer support

  • Dedicated support team for seamless patient and provider assistance
  • Complimentary patient education with board-certified Genetic Counselors
  • Affordable testing options to ensure access for all eligible patients

Seamless efficiency

  • Fast turnaround times to meet urgent clinical needs
  • Efficient processes to reduce administrative burden and free up staff time
  • EMR integration for seamless ordering and access to results

Myriad Oncology empowers you to transform patient care

We offer a suite of services and workflow solutions designed to streamline germline and tumor genomic testing without added cost to the clinic or patient.

Accurate, useful results

  • Accurate, reliable, and actionable results to support informed decisions
  • Clear and easy-to-interpret reports for confident clinical direction
  • Lifetime commitment to variant reclassification

Unmatched customer support

  • Dedicated support team for seamless patient and provider assistance
  • Complimentary patient education with board-certified Genetic Counselors
  • Affordable testing options to ensure access for all eligible patients

Seamless efficiency

  • Fast turnaround times to meet urgent clinical needs
  • Efficient processes to reduce administrative burden and free up staff time
  • EMR integration for seamless ordering and access to results

Personalize management and treatment strategies for more patients throughout their journey

Find the right test for each patient you treat.


Updated guidelines affirm the importance of germline and tumor genomic testing

While tumor genomic testing has long been recommended for patients with metastatic or advanced cancers, ASCO now supports the expansion of multigene germline testing to better ensure eligible patients and their families receive optimal care.3

  • ASCO now advises germline testing for patients who meet guidelines regardless of their tumor results, to ensure comprehensive detection of pathogenic variants and optimized treatment planning3
  • National guidelines recommend germline testing in the workup for patients diagnosed with, or after confirmation of, ovarian, breast, pancreatic, prostate, and colon cancer2
  • All patients with breast cancer meet criteria for germline genetic testing regardless of family history or age16

Image of Carol, a Myriad Oncology female patient

 Meet Carol, a patient empowered through Myriad Oncology portfolio of genetic tests image

Streamlined germline and tumor genomic testing

Ordering both germline and tumor genomic testing from Myriad ensures consolidated and concordant results at each step, empowering you to deliver a truly personalized treatment strategy for each patient.

With Myriad, you will benefit from a streamlined experience for obtaining consolidated germline and tumor genomic results:

  • A guideline-aligned testing approach supports clinical decisions by incorporating comprehensive germline and tumor genomic testing
  • Consolidated germline and tumor genomic results are available within 14 days
  • Dedicated support team for seamless patient and provider assistance
  • Streamlined germline and tumor genomic results in one cohesive report, including a simple summary of key findings for all tests ordered in one sheet

A partner to you and your patients

Myriad has invested over 30 years into developing tests and solutions that help you, your patients, and your practice by providing the best answers and care possible. See how we can help streamline your patient care:

Helpful tools to quickly identify patients who meet criteria for germline testing based on guidelines

Pre-test education as live, point-of-care sessions with a board-certified Genetic Counselor, including documented case notes

Easy ordering options including paper, online, virtual, and EMR for seamless ordering and access to results

Transparent pricing with personalized cost estimates, financial assistance, and other affordability options including direct pay

Tissue specialists ensure tumor tissue is quickly processed, and any unused tissue is promptly returned to the pathology lab

Consolidated germline and tumor genomic results are available within 14 days

The Myriad Management Tool streamlines germline and tumor genomic results into an easy-to-follow report

Medical Science Liasons support you and your team in addressing clinical, testing, and results-related questions

Post-test results consults with board-certified Genetic Counselors can be scheduled or are available on demand

Myriad’s Variant Classification Program includes a Lifetime Reclassification Commitment to send amended reports if a VUS is reclassified and is clinically

Myriad Oncology resources

0

Myriad Live

View discussions about current topics in genetic and tumor genomic testing with Myriad’s medical experts and external special guests. See more details on upcoming events and view past recordings.

0

Latest studies & publications

Stay current with clinical validation and utility publications and more.

0

Documents & forms

Find the Myriad documents and forms you need right here.

References:

  1. Mabey B, Hughes E, Kucera M, et al. Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors. Genet Med. 2024;26(7):101128.
  2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. V1.2025. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed October 9, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  3. Tung N, Ricker C, Messersmith H, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024;42(21):2599-2615.
  4. Judkins T, Leclair B, Bowles K, et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. BMC Cancer. 2015;15:215.
  5. Mundt E, Iorg G. Driving Down the Rate of Variants of Uncertain Significance as the Myriad MyRisk® Multigene Panel Grows [White paper]. Myriad Genetics. 2020.
  6. Gradishar W, Johnson K, Brown K, et al. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. Oncologist. 2017;22(7):797-803.
  7. Timms KM, Abkevich V, Hughes E, et al. Comparison of genomic instability test scores used for predicting PARP activity in ovarian cancer. J Clin Oncol. 2020;38(15_suppl):1586.
  8. Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012-6020.
  9. Filipits M, Sestak I, Buus R, et al. Prediction of distant recurrence using EndoPredict among women with ER+, HER2− node-positive and node-negative breast cancer treated with endocrine therapy only. Clin Cancer Res. 2019;25(13):3865-3872.
  10. Sestak I, Martín M, Dubsky P, et al. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019;176(2):377-386.
  11. Conroy JM, Pabla S, Glenn ST, et al. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. PLoS One. 2021;16(12):e0260089.
  12. Tew WP, Lacchetti C, Birrer MJ, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38(30):3468-3493.
  13. Chakravarty D, Johnson A, Sklar J, et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. J Clin Oncol. 2022;40(11):1231-1258.
  14. Sadik H, Pritchard D, Keeling DM, et al. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2022;6:e2200246.
  15. Manahan ER, Kuerer HM, Sebastian M, et al. Consensus Guidelines on Genetic Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26(10):3025-3031.
  16. The American Society of Breast Surgeons. Consensus guidelines on genetic testing for hereditary breast cancer. 2019.

Myriad Genetics, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific.